Overview

Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors

Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the administration of the amlodipine/atorvastatin single pill to be appropriate
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Amlodipine
Amlodipine, atorvastatin drug combination
Atorvastatin
Atorvastatin Calcium